Holly Guy

Statistics

Publications

Citations

H-Index

Active since

2018

Affiliations

National Cancer Research Institute(Current)

Holly Guy is an author at National Cancer Research Institute specializing in maintenance therapy trials, niraparib therapy, and cost-effectiveness analysis.

ORCID

Publications per year

2018–2019

Publications

Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States

Holly Guy, Lydia Walder, Mark Fisher · PharmacoEconomics · 2018 · 47 citations · Full text

Medicine, Oncology, Pharmacoeconomics +14

Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial

Ursula A. Matulonis, Lydia Walder, Trine Jakobi Nøttrup et al. · Journal of Clinical Oncology · 2019 · 37 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States

Holly Guy, Vicki Laskier, Mark Fisher et al. · PharmacoEconomics · 2018 · 14 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

1–3 of 3